In an exclusive 'Face the Nation' interview, Nobel laureate María Corina Machado discusses Venezuela's future after U.S. intervention, while domestic debates over ICE tactics and a partial government shutdown highlight deepening political divisions.
A federal judge ordered the release of a young child and his father from immigration detention, sparking renewed debate over family detention policies. The pair were reunited with their community after a brief but contentious custody.
A significant purchase of the VictoryShares USAA Core Short-Term Bond ETF (USTB) by wealth manager Merit Financial Group highlights institutional interest in short-duration, income-focused strategies amid market uncertainty.
NextEra Energy is aggressively pursuing long-term power supply agreements with major technology firms, positioning itself as a one-stop shop for clean, reliable electricity to fuel the data center boom. Its strategy hinges on a three-pronged approach: record renewable energy additions, potential nuclear fleet expansion, and a pioneering gas plant with carbon capture technology developed with ExxonMobil.
Facing an eighth consecutive month of declining deliveries, Li Auto is restructuring its R&D and betting on its upgraded L9 model. Amid a falling share price, analysts debate whether the current valuation presents a buying opportunity or reflects deeper challenges.
Tesla's stock is navigating turbulent waters, with a recent one-day surge contrasting sharply against a weaker quarterly performance. As the EV pioneer's share price hovers above some analyst targets, investors are left weighing its ambitious robotaxi and AI-driven future against more conservative valuation models.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
A fatal bus crash in southern Turkey's Antalya province has claimed nine lives and injured 26 others, with authorities citing wet roads, fog, and suspected speeding as contributing factors in the Sunday morning tragedy.
The 179-year-old tobacco giant Philip Morris International is closing its Richmond, Virginia office, eliminating 135 positions, as it aggressively restructures around its smoke-free product portfolio, led by the ZYN nicotine pouch brand.
The Northern Ireland Executive has suspended a planned revaluation of hotel business rates, averting significant tax increases for accommodation providers slated for 2026 and providing temporary stability for the region's tourism industry.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
With shares of the global sustainability leader up nearly 7x over three years, investors are grappling with a critical question: has the market run too far ahead of fundamentals? A deep dive into valuation metrics suggests caution may be warranted.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
AI infrastructure provider CoreWeave finds itself at a critical juncture, buoyed by a deepened $2 billion partnership with chip giant Nvidia while simultaneously defending against securities lawsuits. Investors are weighing the promise of accelerated growth against allegations of misleading disclosures, creating a volatile mix for the high-flying stock.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
The Malaysian healthcare provider KPJ Healthcare Berhad is demonstrating a strengthened capacity for profitable reinvestment, with its return on capital employed rising to 11% alongside significant capital expansion, pointing to a robust operational model.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
Archer Aviation secures a pivotal agreement with Serbia to supply its electric air taxis for EXPO 2027, marking a significant step into the European market and sparking discussions on its path to commercialization and valuation.
As Apple's stock experiences recent volatility, investors are grappling with a critical question: does its current price reflect its long-term potential? A deep dive into valuation models reveals a complex picture, with traditional metrics painting conflicting signals about the iPhone maker's true worth.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
